Lonza Walkersville and Hyglos, a German biotech company, announced today that they have reached a mutually beneficial global settlement which includes a license agreement for Hyglos under certain Lonza patents in the area of endotoxin detection. Specifically, the agreement allows Hyglos to use recombinant factor C technology protected by Lonza's patents to produce Hyglos' own endotoxin products.

The agreement also includes the dismissal of the lawsuit Lonza previously filed against Hyglos.

The terms of the settlement are confidential.